Tag Archives: NSCLC

Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

Scientists attempted to clarify whether apigenin could improve the antitumor efficiency of cisplatin in lung cancer using cancer stem cells.
[Nutrition and Cancer-An International Journal]
Li, Y., Chen, X., He, W., Xia, S., Jiang, X., Li, X., Bai, J., Li, N., Chen, L., & Yang, B. (2020). Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells. Nutrition and Cancer, 0(0), 1–9. https://doi.org/10.1080/01635581.2020.1802494 Cite
Abstract

Continue reading “Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, and TAGRISSO, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
[Daiichi Sankyo Company, Limited]
Press Release

Continue reading “Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in Phase I clinical development for non-small cell lung cancer and TNBC.
[Daiichi Sankyo Ltd.]
Press Release

Continue reading “Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062”

Bookmark

No account yet? Register

0
Share

Rozlytrek, Roche’s First Tumor-Agnostic Therapy, Approved in Europe for People with NTRK Fusion-Positive Solid Tumors and for People with ROS1-Positive Advanced Non-Small Cell Lung Cancer

Roche announced that the European Commission has granted conditional marketing authorisation for Rozlytrek® for the treatment of adult and paediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options.
[F. Hoffmann-La Roche Ltd]
Press Release

Continue reading “Rozlytrek, Roche’s First Tumor-Agnostic Therapy, Approved in Europe for People with NTRK Fusion-Positive Solid Tumors and for People with ROS1-Positive Advanced Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

miR-4634 Augments the Anti-Tumor Effects of RAD001 and Associates Well with Clinical Prognosis of Non-Small Cell Lung Cancer

miRNA microarray analysis showed that miR-4634 levels in A549 cells increased significantly after everolimus treatment. Decreased expression of miR-4634 was also found in non-small-cell lung carcinoma cell lines and patients’ tumors by qPCR.
[Scientific Reports]
Liu, S., Zang, H., Zheng, H., Wang, W., Wen, Q., Zhan, Y., Yang, Y., Ning, Y., Wang, H., & Fan, S. (2020). miR-4634 augments the anti-tumor effects of RAD001 and associates well with clinical prognosis of non-small cell lung cancer. Scientific Reports, 10(1), 13079. https://doi.org/10.1038/s41598-020-70157-0 Cite
Full Article

Continue reading “miR-4634 Augments the Anti-Tumor Effects of RAD001 and Associates Well with Clinical Prognosis of Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

miR-135a Inhibits Non-Small Cell Lung Cancer Progression by Suppressing RAB1B Expression and the RAS Pathway

Researchers showed that miR-135a was aberrantly downregulated in non-small cell lung cancer (NSCLC) cells in comparison with normal bronchial epithelial cells, and the expression of miR-135a inhibited proliferation, invasion and metastasis of NSCLC cells in vitro.
[Aging]
Aging | MiR-135a inhibits non-small cell lung cancer progression by suppressing RAB1B expression and the RAS pathway - Full Text. (n.d.). Retrieved July 31, 2020, from https://www.aging-us.com/article/103494/text Cite
Full Article

Continue reading “miR-135a Inhibits Non-Small Cell Lung Cancer Progression by Suppressing RAB1B Expression and the RAS Pathway”

Bookmark

No account yet? Register

0
Share

LINC00324 Affects Non-Small Cell Lung Cancer Cell Proliferation and Invasion through Regulation of the miR-139-5p/IGF1R Axis

Scientists demonstrated whether LINC00324 participates in non-small cell lung cancer pathogenesis through other molecular mechanism.
[Molecular and Cellular Biochemistry]
Zhang, M., Lin, B., Liu, Y., Huang, T., Chen, M., Lian, D., Deng, S., & Zhuang, C. (2020). LINC00324 affects non-small cell lung cancer cell proliferation and invasion through regulation of the miR-139-5p/IGF1R axis. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-020-03819-2 Cite
Abstract

Continue reading “LINC00324 Affects Non-Small Cell Lung Cancer Cell Proliferation and Invasion through Regulation of the miR-139-5p/IGF1R Axis”

Bookmark

No account yet? Register

0
Share

Comprehensive Analysis of Circular RNA Expression Profiles in Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines

Two cisplatin-resistant non-small cell lung cancer cell lines were established by gradually increasing concentrations of cisplatin in the media. The resulting cell lines possessed high resistance to cisplatin and strong proliferation, migration, and colony formation abilities compared to the parental cells.
[Acta Biochimica Et Biophysica Sinica]
Song, L., Cui, Z., & Guo, X. (n.d.). Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines. Acta Biochimica et Biophysica Sinica. https://doi.org/10.1093/abbs/gmaa085 Cite
Abstract

Continue reading “Comprehensive Analysis of Circular RNA Expression Profiles in Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines”

Bookmark

No account yet? Register

0
Share

Pulmonary Toxicity of Systemic Lung Cancer Therapy

Pulmonary toxicity from taxanes presents as an ILD‐type reaction characterized by increasing dyspnoea, dry cough, fever and bilateral pulmonary interstitial infiltrates.
[Respirology]
Long, K., & Suresh, K. (n.d.). Pulmonary toxicity of systemic lung cancer therapy. Respirology, n/a(n/a). https://doi.org/10.1111/resp.13915 Cite
Full Article

Continue reading “Pulmonary Toxicity of Systemic Lung Cancer Therapy”

Bookmark

No account yet? Register

0
Share

Impaired AKT Signaling and Lung Tumorigenesis by PIERCE1 Ablation in KRAS-Mutant Non-Small Cell Lung Cancer

Investigators showed the tumor-promoting function of a cell cycle-related protein, PIERCE1, in KRAS-mutant non-small cell lung cancer. Mechanistically, PIERCE1 depletion inhibited cell growth and AKT phosphorylation at S473, which was particularly observed in KRAS-mutant lung cancers.
[Oncogene]
Full Article

Continue reading “Impaired AKT Signaling and Lung Tumorigenesis by PIERCE1 Ablation in KRAS-Mutant Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

CircSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer by Targeting miR-520h/ABCG2 Pathway

The authors determined circSETD3 was significantly upregulated in gefitinib-resistant non-small cell lung cancer (NSCLC) cell lines and the plasma of gefitinib-resistant NSCLC patients.
[Molecular Therapy-Nucleic Acids]
AbstractGraphical Abstract

Continue reading “CircSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer by Targeting miR-520h/ABCG2 Pathway”

Bookmark

No account yet? Register

0
Share

NRF2-GPX4/SOD2 Axis Imparts Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cells

The authors investigated the role of NRF2 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). They showed that NRF2 protein levels were markedly increased in a panel of EGFR-TKI-resistant non-small cell lung cancer cell lines due to slow degradation of NRF2 protein.
[Acta Pharmacologica Sinica]
Abstract

Continue reading “NRF2-GPX4/SOD2 Axis Imparts Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cells”

Bookmark

No account yet? Register

0
Share
Share